RPL22L1

Across TCGA pan-cancer cohorts, RPL22L1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL22L1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPL22L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL22L1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where RPL22L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	IV	0.194	0.956	.038	6	view →
GBM	DFS	Median	All	0.497	0.246	.013	5	view →
LUAD	DFS	Median	All	0.802	0.520	.004	5	view →
UCEC	DFS	Quartile	II,III,IV	0.475	0.883	.040	4	view →
CCRCC	DFS	Quartile	III,IV	0.311	0.793	.024	3	view →
HNSC	OS	Quartile	All	0.611	0.853	.013	1	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL22L1–PDAC (OS)

Open the PDAC breakdown →